Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen's Repatha Emerges Unscathed In GLAGOV PCSK9 Imaging Study

Executive Summary

Full data from GLAGOV imaging study shows value of driving LDL below 60 mg/dL and presents no red flags for outcomes data due in first quarter of 2017.

You may also be interested in...



Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition

Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.

GLAGOV Imaging Study Of Amgen's Repatha Bodes Well For PCSK9 Class

Positive results in GLAGOV lift PCSK9 inhibitor Repatha, but most likely are still not enough to get rid of reimbursement restrictions for the class, analysts say.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel